

ASX ANNOUNCEMENT

ASX: 1AI | 30 June 2026

Change of Company Secretary

AI-enabled pharmaceutical company **Algorae Pharmaceuticals Ltd (ASX: 1AI)** ("Algorae" or "the Company") is pleased to advise the appointment of Mrs Geraldine Holland and Ms Catherine Earlie as Joint Company Secretaries, effective 1 July 2026.

Mrs Holland is an experienced governance professional with more than 15 years' experience in company secretarial practice and corporate governance across both listed and unlisted companies.

Ms Earlie is an experienced governance and legal professional, with a strong background in corporate compliance and advisory.

Ms Jennifer Voon will step down as Company Secretary effectively today. The Board expresses its sincere gratitude to Ms Voon for her valued contributions, commitment and dedicated service to the Company.

For the purpose of ASX Listing Rule 12.6, Mrs Holland and Ms Earlie are responsible for communications between the Company and ASX.

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: investors@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Securities Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.